Massimo Triggiani

Dr. Massimo Triggiani

Division of Allergy and Clinical Immunology University of Salerno, Salerno, Italy
orcid

Research Focus & Metrics

Academic Career Length

45Years (1982-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 May 2007 in European Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
Peter ValentPeter Valent
Peter Valent
CACem Akin
Cem Akin
LEL. Escribano
L. Escribano
MFM. Födinger
M. Födinger
KHKarin Hartmann
Karin Hartmann
DMD. D. Metcalfe
D. D. Metcalfe
Although a classification for mastocytosis and diagnostic criteria are available, there remains a need to define standards for the application of diagnostic tests, clinical evaluations, and treatment responses. To address these demands, leading experts discussed current issues and standards in mastocytosis in a Working Conference. The present article provides the resulting outcome with consensus statements, which focus on the appropriate application of clinical and laboratory tests, patient selection for interventional therapy, and the selection of appropriate drugs. In addition, treatment response criteria for the various clinical conditions, disease‐specific symptoms, and specific pathologies are provided. Resulting recommendations and algorithms should greatly facilitate the management of patients with mastocytosis in clinical practice, selection of patients for therapies, and the conduct of clinical trials.

27 March 2014 in Allergy
Verified
Journal Article
Closed access
PDF file
MCM. Cicardi
M. Cicardi
WAW. Aberer
W. Aberer
ABA. Banerji
A. Banerji
MBM. Bas
M. Bas
JBJ. A. Bernstein
J. A. Bernstein
UHUnder The Patronage Of Eaaci (European Academy Of Allergy And Clinical Immunology) Hawk
Under The Patronage Of Eaaci (European Academy Of Allergy And Clinical Immunology) Hawk

27 October 2011 in International Archives of Allergy and Immunology
Verified
Journal Article
Open access
PDF file
Peter ValentPeter Valent
Peter Valent
CACem Akin
Cem Akin
MAMichel Arock
Michel Arock
KBKnut Brockow
Knut Brockow
JBJoseph H. Butterfield
Joseph H. Butterfield
DMDean D. Metcalfe
Dean D. Metcalfe
Activation of tissue mast cells (MCs) and their abnormal growth and accumulation in various organs are typically found in primary MC disorders also referred to as mastocytosis. However, increasing numbers of patients are now being informed that their clinical findings are due to MC activation (MCA) that is neither associated with mastocytosis nor with a defined allergic or inflammatory reaction. In other patients with MCA, MCs appear to be clonal cells, but criteria for diagnosing mastocytosis are not met. A working conference was organized in 2010 with the aim to define criteria for diagnosing MCA and related disorders, and to propose a global unifying classification of all MC disorders and pathologic MC reactions. This classification includes three types of ‘MCA syndromes’ (MCASs), namely primary MCAS, secondary MCAS and idiopathic MCAS. MCA is now defined by robust and generally applicable criteria, including (1) typical clinical symptoms, (2) a substantial transient increase in serum total tryptase level or an increase in other MC-derived mediators, such as histamine or prostaglandin D2, or their urinary metabolites, and (3) a response of clinical symptoms to agents that attenuate the production or activities of MC mediators. These criteria should assist in the identification and diagnosis of patients with MCAS, and in avoiding misdiagnoses or overinterpretation of clinical symptoms in daily practice. Moreover, the MCAS concept should stimulate research in order to identify and exploit new molecular mechanisms and therapeutic targets.

1 January 2016 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
KHKarin Hartmann
Karin Hartmann
LELuis Escribano
Luis Escribano
CGClive Grattan
Clive Grattan
KBKnut Brockow
Knut Brockow
MCMelody C. Carter
Melody C. Carter
Peter ValentPeter Valent
Peter Valent

4 February 2015 in Leukemia
Verified
Journal Article
Closed access
PDF file
MAMichel Arock
Michel Arock
KSK Sotlar
K Sotlar
CACem Akin
Cem Akin
SBS Broesby-Olsen
S Broesby-Olsen
GHGregor Hörmann
Gregor Hörmann
Peter ValentPeter Valent
Peter Valent

14 March 2017 in Cancer Research
Verified
Journal Article
Closed access
PDF file
Peter ValentPeter Valent
Peter Valent
CACem Akin
Cem Akin
KHKarin Hartmann
Karin Hartmann
GNGunnar Nilsson
Gunnar Nilsson
ARAndreas Reiter
Andreas Reiter
DMDean D. Metcalfe
Dean D. Metcalfe
Mastocytosis is a term used to denote a heterogeneous group of conditions defined by the expansion and accumulation of clonal (neoplastic) tissue mast cells in various organs. The classification of the World Health Organization (WHO) divides the disease into cutaneous mastocytosis, systemic mastocytosis, and localized mast cell tumors. On the basis of histomorphologic criteria, clinical parameters, and organ involvement, systemic mastocytosis is further divided into indolent systemic mastocytosis and advanced systemic mastocytosis variants, including aggressive systemic mastocytosis and mast cell leukemia. The clinical impact and prognostic value of this classification has been confirmed in numerous studies, and its basic concept remains valid. However, refinements have recently been proposed by the consensus group, the WHO, and the European Competence Network on Mastocytosis. In addition, new treatment options are available for patients with advanced systemic mastocytosis, including allogeneic hematopoietic stem cell transplantation and multikinase inhibitors directed against KIT D816V and other key signaling molecules. Our current article provides an overview of recent advances in the field of mastocytosis, with emphasis on classification, prognostication, and emerging new treatment options in advanced systemic mastocytosis. Cancer Res; 77(6); 1261–70. ©2017 AACR.